U.S. Markets open in 1 hr 7 mins

Boulder biotech firm enters reverse merger valued at up to $60 million

Jensen Werley
Boulder biotech firm enters reverse merger valued at up to $60 million

Brickell Biotech Inc., a Boulder-based medical dermatology company, is merging with Vical Inc. (Nasdaq: VICL). Under the terms of the agreement, the combined company will be named Brickell Biotech, keep the management team of Brickell and be headquartered in Boulder. The deal, a reverse merger, will mean Brickell acquires the $35 million that San Diego-based Vical has available as well as its listing on the Nasdaq.